Actively Recruiting
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Led by FindCure Biosciences (ZhongShan) Co., Ltd. · Updated on 2026-03-10
33
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
CONDITIONS
Official Title
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years old male and female.
- Phase Ib: Patients with histologically or cytologically diagnosed solid tumors who have failed standard therapy.
- Phase IIa: Patients with histologically or cytologically confirmed stage IIIB/IIIC and stage IV NSCLC not suitable for surgery or radiotherapy.
- No known sensitizing mutations or actionable oncogenes with approved therapies available.
- Prior PD-1/PD-L1 inhibitor combined with platinum-containing therapy has failed.
- At least one measurable lesion according to RECIST 1.1.
- ECOG performance status 0-1.
- Major organs functioning well.
You will not qualify if you...
- Not recovered from adverse reactions caused by previous anti-tumor treatments (grade 1 or higher CTCAE).
- Received anti-tumor therapy within 4 weeks before enrollment.
- Participated in other clinical trials within 4 weeks before enrollment and used investigational drugs during this time.
- Undergone surgery within 4 weeks before enrollment without sufficient recovery to start the study.
- Presence of uncontrolled ascites, pleural effusion, or pericardial effusion.
- Central nervous system metastases with clinical symptoms.
- Other conditions deemed by the researcher as inappropriate for participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai East Hospital
Shanghai, Shanghai Municipality, China, 200120
Actively Recruiting
Research Team
T
Tingjin Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here